etoposide has been researched along with carbostyril in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (52.17) | 18.2507 |
| 2000's | 7 (30.43) | 29.6817 |
| 2010's | 4 (17.39) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gootz, TD; Martin, BA; McGuirk, PR; Moynihan, M; Osheroff, N; Robinson, MJ; Sutcliffe, JA | 1 |
| Chung, IK; Gootz, TD; McGuirk, PR; Muller, MT; Spitzner, JR | 1 |
| Elsea, SH; Hsiung, Y; Nitiss, JL; Osheroff, N | 1 |
| Forsgren, A; Riesbeck, K | 1 |
| Corbett, AH; Elsea, SH; Osheroff, N; Westergaard, M | 1 |
| Corbett, AH; Osheroff, N; Robinson, MJ | 1 |
| Corbett, AH; Hong, D; Osheroff, N | 1 |
| Arakawa, H; Iguchi, T; Kurama, M; Mano, E; Nakagawa, S; Okura, A; Tanaka, N; Yoshinari, T | 1 |
| Burden, DA; Elsea, SH; Lomenick, JP; Osheroff, N; Westergaard, M | 1 |
| Nicklaus, MC; Nitiss, JL; Pommier, Y; Rose, A; Strumberg, D | 1 |
| Barrows, LR; Haughey, HM; Holden, JA; Ireland, CM; Matsumoto, SS; Schmehl, DM; Venables, DA | 1 |
| Anderson, VE; Gootz, TD; Kaczmarek, FS; Osheroff, N; Zaniewski, RP | 1 |
| Béhard, A; Collignon, F; Darro, F; Decaestecker, C; Frydman, A; Guillaumet, G; Joseph, B; Kiss, R; Lesur, B | 1 |
| Campbell, AK; Chin, SF; Davies, S; Errington, RJ; Smith, PJ; Wiltshire, M | 1 |
| Smit, EF | 1 |
| Gruger, T; Heisig, P; Maxwell, A; Nitiss, JL; Pommier, Y; Seeber, S; Strumberg, D; Zechiedrich, EL | 1 |
| Alsina, M; Beaupre, DM; Buzzeo, R; Dalton, WS; Enkemann, S; Lichtenheld, MG; Nimmanapalli, R | 1 |
| Adjei, AA; Dai, NT; Feldman, EJ; Flatten, K; Garrett-Mayer, E; Gore, SD; Greer, JM; Ironside, V; Karp, JE; Kaufmann, SH; Le, SB; Levis, MJ; Loegering, DA; Meng, XW; Morris, LE; Ricklis, RM; Ritchie, E; Roboz, G; Schneider, PA; Smith, BD; Talbott, T; Wright, JJ | 1 |
| Karp, J | 1 |
| Arkin, MR; Byl, JA; Conroy, A; Fox, JA; Hawtin, RE; McDowell, RS; Nguyen, T; Osheroff, N; Stockett, DE; Yang, W | 1 |
| Leo, E; Marchand, C; Pommier, Y; Zhang, H | 1 |
| Carraway, HE; Derecho, C; Feldman, EJ; Galkin, S; Garret-Mayer, E; Gocke, CD; Gore, SD; Greer, JM; Ironside, V; Karp, JE; Kaufmann, SH; Levis, MJ; Malek, S; McDevitt, MA; Morris, LE; Palma, J; Raponi, M; Ritchie, EK; Roboz, GR; Smith, BD; Vener, TI; Wang, Y; Wright, JJ | 1 |
| Christos, PJ; Feldman, EJ; Gergis, U; Mayer, S; Ritchie, EK; Roboz, GJ; Scandura, JM; Wissa, U | 1 |
2 review(s) available for etoposide and carbostyril
| Article | Year |
|---|---|
Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes.
Topics: Amsacrine; Animals; Anti-Infective Agents; Antineoplastic Agents; DNA; DNA Damage; DNA Topoisomerases, Type II; Etoposide; Fluoroquinolones; Genistein; Humans; Isoflavones; Models, Structural; Quinolones; Topoisomerase II Inhibitors | 1994 |
DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Camptothecin; DNA Topoisomerases; Doxorubicin; Enzyme Inhibitors; Etoposide; Humans; Mitoxantrone; Quinolones; Topoisomerase Inhibitors | 2010 |
2 trial(s) available for etoposide and carbostyril
| Article | Year |
|---|---|
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.
Topics: Administration, Oral; Age of Onset; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Etoposide; Farnesyltranstransferase; HL-60 Cells; Humans; Jurkat Cells; Leukemia, Myeloid, Acute; Quinolones; Tumor Cells, Cultured; U937 Cells | 2009 |
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; DNA-Binding Proteins; Etoposide; Female; Follow-Up Studies; Guanine Nucleotide Exchange Factors; Humans; Leukemia, Myeloid, Acute; Male; Nuclear Proteins; Pharmacogenetics; Prognosis; Quinolones; Remission Induction; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate | 2012 |
19 other study(ies) available for etoposide and carbostyril
| Article | Year |
|---|---|
Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage.
Topics: Animals; Anti-Infective Agents; Catalysis; Cell Line; Cell Survival; Cricetinae; Cricetulus; DNA; DNA Topoisomerases, Type II; Drosophila melanogaster; Electrophoresis, Agar Gel; Etoposide; Fluoroquinolones; Hydrolysis; Molecular Structure; Quinolones | 1991 |
Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
Topics: Amsacrine; Anti-Infective Agents; Base Sequence; DNA; DNA Topoisomerases, Type II; Etoposide; Fluoroquinolones; Humans; Hydrolysis; Molecular Sequence Data; Quinolones; Teniposide; Topoisomerase II Inhibitors | 1995 |
A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors.
Topics: Anti-Infective Agents; Base Sequence; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Escherichia coli; Etoposide; Fluoroquinolones; Genes, Bacterial; Genes, Fungal; Kinetics; Macromolecular Substances; Molecular Sequence Data; Mutagenesis, Site-Directed; Oligodeoxyribonucleotides; Point Mutation; Quinolones; Recombinant Proteins; Saccharomyces cerevisiae; Serine; Species Specificity; Tryptophan | 1995 |
CP-115,953 stimulates cytokine production by lymphocytes.
Topics: Anti-Infective Agents; Cells, Cultured; Cytokines; DNA Damage; Etoposide; Fluoroquinolones; Humans; Interferon-gamma; Interleukin-2; Lymphocyte Activation; Novobiocin; Quinolones; RNA, Messenger; T-Lymphocytes; Thymidine; Topoisomerase II Inhibitors | 1995 |
Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II.
Topics: Adenosine Triphosphate; Amsacrine; Animals; Anti-Infective Agents; Antineoplastic Agents; Binding Sites; Cell Nucleus; DNA Topoisomerases, Type II; DNA, Bacterial; Drosophila melanogaster; Escherichia coli; Etoposide; Fluoroquinolones; Genistein; Hydrolysis; Isoflavones; Novobiocin; Plasmids; Quercetin; Quinolones; Topoisomerase II Inhibitors | 1993 |
Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme.
Topics: Amsacrine; Animals; Anti-Infective Agents; Binding Sites; Cell Line; Cell Nucleus; DNA; DNA Topoisomerases, Type II; DNA, Superhelical; Drosophila melanogaster; Drug Interactions; Etoposide; Fluoroquinolones; Genistein; Growth Inhibitors; Isoflavones; Kinetics; Novobiocin; Protein Binding; Quinolones; Structure-Activity Relationship; Topoisomerase II Inhibitors | 1993 |
Stereo (C7)-dependent topoisomerase II inhibition and tumor growth suppression by a new quinolone, BO-2367.
Topics: Animals; Anti-Infective Agents; Carcinoma; Colonic Neoplasms; DNA Topoisomerases, Type II; DNA, Neoplasm; DNA, Superhelical; Drug Screening Assays, Antitumor; Enzyme Induction; Etoposide; Female; Fluoroquinolones; Leukemia L1210; Leukemia P388; Mice; Mice, Inbred Strains; Quinolones; Stereoisomerism; Topoisomerase II Inhibitors | 1993 |
Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Topics: Amsacrine; Animals; Anti-Infective Agents; Antineoplastic Agents; Binding Sites; CHO Cells; Ciprofloxacin; Cricetinae; DNA Topoisomerases, Type II; DNA, Superhelical; Drosophila melanogaster; Electrophoresis, Agar Gel; Enzyme Activation; Etoposide; Fluoroquinolones; Genistein; Isoflavones; Kinetics; Molecular Structure; Quinolones | 1997 |
Mutation of a conserved serine residue in a quinolone-resistant type II topoisomerase alters the enzyme-DNA and drug interactions.
Topics: Amino Acid Substitution; Base Sequence; DNA; DNA Primers; DNA Topoisomerases, Type II; Enzyme Stability; Etoposide; Hot Temperature; Hydrolysis; Protein Conformation; Quinolones; Recombinant Proteins; Salts; Serine | 1999 |
Makaluvamines vary in ability to induce dose-dependent DNA cleavage via topoisomerase II interaction.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; DNA; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Humans; Mice; Mice, Nude; Nasopharyngeal Neoplasms; Pyrroles; Quinolones; Topoisomerase II Inhibitors | 1999 |
Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries.
Topics: Anti-Infective Agents; Biological Evolution; Ciprofloxacin; DNA Damage; DNA Repair; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Escherichia coli; Etoposide; Fluoroquinolones; Gram-Positive Bacteria; Kinetics; Quinolones; Staphylococcus aureus | 1999 |
3-Aryl-2-quinolone derivatives: synthesis and characterization of in vitro and in vivo antitumor effects with emphasis on a new therapeutical target connected with cell migration.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Movement; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Humans; Mammary Neoplasms, Experimental; Mice; Microscopy, Phase-Contrast; Neoplasm Transplantation; Quinolones; Structure-Activity Relationship; Tetrazoles; Tumor Cells, Cultured | 2002 |
DNA damage-induced [Zn(2+)](i) transients: correlation with cell cycle arrest and apoptosis in lymphoma cells.
Topics: Apoptosis; Cell Cycle; Chelating Agents; Cytoplasm; DNA Damage; Ethylenediamines; Etoposide; Fluorescent Dyes; Humans; Lymphoma; Nucleic Acid Synthesis Inhibitors; Osmolar Concentration; Quinolones; Subcellular Fractions; Tosyl Compounds; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Zinc | 2002 |
[New data presented at ASCO 2002 concerning small cell bronchial cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Prognosis; Pyrimidines; Quinolones; Smoking; Smoking Prevention; Survival Analysis; Treatment Outcome | 2002 |
A mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase II.
Topics: Anti-Bacterial Agents; Chromosome Mapping; DNA Gyrase; DNA, Superhelical; Drug Resistance, Bacterial; Enzyme Inhibitors; Escherichia coli; Etoposide; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Plasmids; Point Mutation; Quinolones; Reverse Transcriptase Polymerase Chain Reaction; Teniposide; Time Factors; Topoisomerase II Inhibitors | 2004 |
Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.
Topics: Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Farnesyltranstransferase; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Melphalan; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Phenotype; Protease Inhibitors; Protein Prenylation; Pyrazines; Quinolones; ras Proteins; Staurosporine; Tunicamycin | 2005 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |
Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; DNA; DNA Damage; DNA Fragmentation; DNA Topoisomerases, Type II; Drug Delivery Systems; Etoposide; G2 Phase; Humans; Intercalating Agents; Naphthyridines; Quinolones; Thiazoles | 2010 |
Are low-intensity induction strategies better for older patients with acute myeloid leukemia?
Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Daunorubicin; Etoposide; Female; Gemtuzumab; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxides; Quinolones; Remission Induction; Retrospective Studies; Treatment Outcome | 2012 |